Nov 27, 2024
"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Jul 31, 2024
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx(TM) System for Administration of nusinersen
Dec 15, 2020
APRINOIA Therapeutics Established Collaboration on Tau PET Imaging Tracer Development
Oct 20, 2020
Abarca Details First Value-Based Agreement For Medicaid Members Prescribed Biogen Products
Sep 03, 2020
OneUnited Bank, Fintech Pioneer, Announces $10 Million Deposit By Biogen To Support #BankBlack Movement
Jul 13, 2020
Initiation Of New Phase III Clinical Study (AHEAD 3-45) Of BAN2401 Preclinical (Asymptomatic) Alzheimer's Disease
Nov 12, 2019
Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY(TM)
Sep 13, 2019
Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
Jul 01, 2019
Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Mar 21, 2019
Neurotrope Comments On Biogen's Discontinued Phase 3 Trial In Alzheimer's Disease
Feb 25, 2019
Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
Jul 25, 2018
Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
Jul 25, 2018
Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
Jul 05, 2018
Eisai And Biogen Announce Positive Topline Results Of The Final Analysis For BAN2401 At 18 Months
Jun 06, 2018
Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program
Dec 15, 2017
Stock Review for Biotech's Investors -- Bioverativ, ACADIA Pharma, Inovio Pharma, and Biogen
Aug 25, 2017
Technical Snapshots for these Biotech Stocks -- Gilead Sciences, Biogen, bluebird bio, and BioMarin Pharma
Jul 28, 2017
Abarca Health Announces Innovative Value-Based Contract With Biogen For Multiple Sclerosis Therapies
Jul 27, 2017
Abarca Health And Biogen Announces Innovative Value-Based Contract For Multiple Sclerosis Therapies